Catalent To Present at INTERPHEX

Article

Catalent will recognize 80 years of softgel advancements with presentations at INTERPHEX.

Catalent will recognize 80 years of softgel advancements at INTERPHEX on March 18-20, 2014 in New York City with presentations from its senior management team, as well as graduates from the company’s Global Operations Leadership Development (GOLD) program.

On Wednesday, March 19, Sridhar Krishnan, Catalent’s vice president, Global Operations, will present “Catalent GOLD - Accelerating Leadership Pipeline in Pharma & Biotech.” Catalent’s GOLD program is a two-year leadership development opportunity, designed for university graduates who have a desire to accelerate their career growth in an entrepreneurial, fast-paced environment. Krishnan’s presentation, which takes place from 10:30 to 11:30 AM, will outline the GOLD leadership model and feature the experiences of three graduates who have participated in the program.

Also on Wednesday 19, from 2:45 to 3:45 PM, Akan Oton, director, Global Licensing & CorporateAlliances, will lead a discussion on “Commercializing Emerging Drug Delivery Technologies.” His presentation will address the evolving role of drug delivery in pharma products from a commercial perspective and will look at current trends in drug delivery and unmet needs currently being pursued. He will also give examples of a typical path to commercialization of drug delivery technologies by innovators.

On Thursday, March 20, from 11:45 AM to 12:45 PM, Bill Hartzel, director, Strategic Execution, Advanced Delivery Technologies will present, “Advanced Aseptic Processing to Reduce Risk with Sterile Fill/Finish.” His presentation will feature ways to identify the QbD elements of Blow/Fill/Seal equipment and the evaluation of the risk mitigation properties of advanced aseptic properties as well astaking a look at Catalent’s newly launched ADVASEPT technology.

Source: Catalent

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content